A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).

David Paul Carbone; Mark A. Socinski; Allen C. Chen; Prabhu Bhagavatheeswaran; Martin Reck; Luis Paz-Ares

doi:10.1200/jco.2014.32.15_suppl.tps8128

A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8128 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8128-TPS8128 ◽

Cited By ~ 4

Author(s):

David Paul Carbone ◽

Mark A. Socinski ◽

Allen C. Chen ◽

Prabhu Bhagavatheeswaran ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Trial

Download Full-text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70046-x ◽

2015 ◽

Vol 16 (3) ◽

pp. 328-337 ◽

Cited By ~ 75

Author(s):

Luis Paz-Ares ◽

Jörg Mezger ◽

Tudor E Ciuleanu ◽

Jürgen R Fischer ◽

Joachim von Pawel ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled

Download Full-text

A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy292.126 ◽

2018 ◽

Vol 29 ◽

pp. viii545 ◽

Cited By ~ 1

Author(s):

F. Wu ◽

G. Gao ◽

C. Zhou ◽

X. Kang ◽

Y. Zhou

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Multicenter Study ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Phase III open-label comparison of gemcitabine/oxaliplatin versus paclitaxel/carboplatin as first line therapy for advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8024 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8024-8024 ◽

Cited By ~ 1

Author(s):

C. H. Weissman ◽

C. H. Reynolds ◽

M. A. Neubauer ◽

I. Steinberg ◽

L. Asmar

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy

Download Full-text

6519 ORAL Favorable benefit to risk profile for pemetrexed plus cisplatin versus gemcitabine plus cisplatin in a large phase III study of first-line therapy in advanced non-small cell lung cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71347-2 ◽

2007 ◽

Vol 5 (4) ◽

pp. 363 ◽

Cited By ~ 2

Author(s):

G. Scagliotti ◽

K. Park ◽

S. Patil ◽

J. Rolski ◽

T. Gorksel ◽

...

Keyword(s):

Lung Cancer ◽

Risk Profile ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Large Phase

Download Full-text

P2-305: Immediate versus delayed docetaxel after first-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer: A Phase III trial report with survival update

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284013.28545.c7 ◽

2007 ◽

Vol 2 (8) ◽

pp. S693-S694

Author(s):

J Schiller ◽

S.R. Dakhil ◽

A.P. Lyss ◽

D.M. Loesch ◽

D Waterhouse ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)00021-2 ◽

2015 ◽

Vol 16 (7) ◽

pp. 763-774 ◽

Cited By ~ 252

Author(s):

Nick Thatcher ◽

Fred R Hirsch ◽

Alexander V Luft ◽

Aleksandra Szczesna ◽

Tudor E Ciuleanu ◽

...

Keyword(s):

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled ◽

Gemcitabine And Cisplatin

Download Full-text

Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.7551 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 7551-7551 ◽

Cited By ~ 1

Author(s):

M. A. Socinski ◽

I. N. Bondarenko ◽

N. A. Karaseva ◽

A. Makhson ◽

I. Vynnychenko ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A randomized, multicenter phase III study of lobaplatin/etoposide versus cisplatin/etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer and circulating tumor cells (CTCs) as an exploratory biomarker.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7595 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7595-7595 ◽

Cited By ~ 2

Author(s):

Ying Cheng ◽

Yun Fan ◽

Xiaoqing Liu ◽

Yunpeng Liu ◽

Jiwei Liu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284110.26459.89 ◽

2007 ◽

Vol 2 (8) ◽

pp. S736-S737

Author(s):

Craig Reynolds ◽

David Barrera ◽

Duy Quoc Vu ◽

Robert Jotte ◽

Alexander I. Spira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdq652 ◽

2011 ◽

Vol 22 (8) ◽

pp. 1798-1804 ◽

Cited By ~ 60

Author(s):

A. Schmittel ◽

M. Sebastian ◽

L. Fischer von Weikersthal ◽

P. Martus ◽

T.C. Gauler ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Extensive Disease ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy

Download Full-text